Literature DB >> 9285793

Nuclear localization of SYT, SSX and the synovial sarcoma-associated SYT-SSX fusion proteins.

N R dos Santos1, D R de Bruijn, M Balemans, B Janssen, F Gärtner, J M Lopes, B de Leeuw, A Geurts van Kessel.   

Abstract

Synovial sarcoma is characterized by a prevalent chromosomal translocation, t(X;18)(p11;q11). As a result of this translocation the SYT gene on chromosome 18 fuses to either the SSX1 or the SSX2 gene on the X chromosome. In this study, we generated polyclonal antibodies against the SYT and SSX2 proteins. These antibodies specifically detected both these proteins and the SYT-SSX fusion proteins in transfected COS-1 cell extracts. Indirect immunofluorescence analysis of COS-1 cells expressing tagged or untagged SYT, SSX2, SYT-SSX1 or SYT-SSX2 indicated that all these proteins are localized in the nucleus, excluding the nucleoli. The SSX2 protein exhibited a diffuse staining pattern whereas both the SYT and SYT-SSX proteins appeared in several nuclear dots. Similar nuclear dots were also detected in primary synovial sarcoma cells growing in a short-term in vitro culture. Double immunofluorescence in conjunction with confocal laser-scanning microscopy revealed that the SYT and SYT-SSX nuclear dots do not co-localize with known nuclear structures as e.g. coiled bodies, SC35 interchromatin granules or PML bodies. The similar nuclear localization patterns of SYT and SYT-SSX suggest that the SYT-SSX fusion proteins are directed to SYT-associated nuclear domains where an abnormal function may be exerted.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9285793     DOI: 10.1093/hmg/6.9.1549

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  17 in total

1.  Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma.

Authors:  Cigall Kadoch; Gerald R Crabtree
Journal:  Cell       Date:  2013-03-28       Impact factor: 41.582

Review 2.  Disruption of mammalian SWI/SNF and polycomb complexes in human sarcomas: mechanisms and therapeutic opportunities.

Authors:  Matthew J McBride; Cigall Kadoch
Journal:  J Pathol       Date:  2018-03-06       Impact factor: 7.996

3.  Detection of SYT-SSX fusion transcripts in both epithelial and spindle cell areas of biphasic synovial sarcoma using laser capture microdissection.

Authors:  T Kasai; S Shimajiri; H Hashimoto
Journal:  Mol Pathol       Date:  2000-04

Review 4.  The SSX family of cancer-testis antigens as target proteins for tumor therapy.

Authors:  Heath A Smith; Douglas G McNeel
Journal:  Clin Dev Immunol       Date:  2010-10-11

5.  Loss of SS18-SSX1 inhibits viability and induces apoptosis in synovial sarcoma.

Authors:  Emily E Carmody Soni; Silke Schlottman; Hayriye V Erkizan; Aykut Uren; Jeffrey A Toretsky
Journal:  Clin Orthop Relat Res       Date:  2014-03       Impact factor: 4.176

6.  Genome-wide recruitment to Polycomb-modified chromatin and activity regulation of the synovial sarcoma oncogene SYT-SSX2.

Authors:  Christina B Garcia; Christian M Shaffer; Josiane E Eid
Journal:  BMC Genomics       Date:  2012-05-17       Impact factor: 3.969

7.  Malignant small round cell tumors.

Authors:  Arvind Rajwanshi; Radhika Srinivas; Gautam Upasana
Journal:  J Cytol       Date:  2009-01       Impact factor: 1.000

8.  Downstream and intermediate interactions of synovial sarcoma-associated fusion oncoproteins and their implication for targeted therapy.

Authors:  Joanna Przybyl; Monika Jurkowska; Piotr Rutkowski; Maria Debiec-Rychter; Janusz A Siedlecki
Journal:  Sarcoma       Date:  2012-03-25

9.  Cancer/testis antigens and gametogenesis: a review and "brain-storming" session.

Authors:  Martins Kalejs; Jekaterina Erenpreisa
Journal:  Cancer Cell Int       Date:  2005-02-16       Impact factor: 5.722

10.  A Role for SMARCB1 in Synovial Sarcomagenesis Reveals That SS18-SSX Induces Canonical BAF Destruction.

Authors:  Jinxiu Li; Timothy S Mulvihill; Li Li; Jared J Barrott; Mary L Nelson; Lena Wagner; Ian C Lock; Amir Pozner; Sydney Lynn Lambert; Benjamin B Ozenberger; Michael B Ward; Allie H Grossmann; Ting Liu; Ana Banito; Bradley R Cairns; Kevin B Jones
Journal:  Cancer Discov       Date:  2021-06-02       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.